A groundbreaking international clincal trial has found that adding the drug apalutamide to standard hormone therapy after prostate removal surgery reduces the risk of cancer recurrence by 29% in men with high-risk prostate cancer. The phase 3 PROTEUS trial, presented at the American Society of Clinical Oncology annual meeting, involved 2,100 men across 18 countries, with an average age of 66. According to the report, all participants received androgen deprivation therapy (ADT) for six months before and after prostatectomy, with half also receiving apalutamide (marketed as Erleada) and the other half a placebo.

29% reduction: What the PROTEUS trial numbers mean

The primary finding from the PROTEUS trial is a 29% reduction in the risk of cancer recurrence among men who received apalutamide plus ADT compared to those on ADT alone. As reported by the study authors, this translates to a median progression-free survival of nearly five years for the apalutamide group versus about three years for the placebo group.. Additionally, the combination therapy lowered the risk of cancer spreading by approximately 20%. These figures, drawn from a rigorous phase 3 trial, provide strong evidence that the drug combination can meaningfully extend remission for high-risk surgical patients.

5 years vs 3 years: The median progression-free survival gap

The almost two-year difference in median progression-free survival between the two groups is a crucial metric for patients and clinicians. A longer period without disease progression means more time without additional aggressive treatments and their side effects. the report notes that after five years, the apalutamide-treated men remained cancer-free for a significantly longer duration.. This data point is especially relevant given that approximately half of all high-risk prostate cancer cases recur after surgery alone, as the source article states.

Why 63,000 UK cases a year make this perosnal

Prostate cancer remains the most prevalent cancer in men in the UK, with about 63,000 new cases and 12,000 deaths annually, according to the source. These trial results arrive just after UK government advisers rejected proposals for a nationwide screening program. The Daily Mail has been campaigning for targeted screening of high-risk groups, including Black men and those with a family history. The PROTEUS findings could strengthen the argument for earlier, more intensive treatment for those at highest risk, though experts like Simon Grieveson of Prostate Cancer UK urge caution about over-treatment.

The side-effect trade-off: rashes and urinary infections

The trial reported that side effects were manageable but not negligible. According to the source, urinary tract infections were common in both groups, but rashes were the most frequent reason for discontinuing apalutamide. Grieveson warned, "However, the extra treatment also caused more serious side effects, and we need to be extremely careful that we aren't over-treating some of these men." This tension between efficacy and toxicity is central to decisions about which patients shoud receive the intensified regimen.

Who should get apalutamide? The lingering question of over-treatment

Researchers are conducting further analyses to determine which patients benefit most from the combination therapy. The source indicates that the trial's results raise key unanswered questions: Can biomarkers identify men who will gain the most without suffering severe side effects? How long should apalutamide be continued beyond the six-month peri-surgical window? And will the progression-free survival advantage translate into a longer overall survival benefit? Without these answers, clinicians must weigh the 29% risk reduction against the potential for adverse events on an individualized basis.